• LAST PRICE
    7.2503
  • TODAY'S CHANGE (%)
    Trending Up0.1003 (1.4028%)
  • Bid / Lots
    7.2000/ 1
  • Ask / Lots
    7.7000/ 4
  • Open / Previous Close
    7.2500 / 7.1500
  • Day Range
    Low 7.2500
    High 7.2503
  • 52 Week Range
    Low 5.2540
    High 17.4000
  • Volume
    1,731
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 7.15
TimeVolumeKTTA
02:45 ET5117.25
03:00 ET5007.25
03:57 ET1007.2503
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKTTA
Pasithea Therapeutics Corp
7.4M
-0.6x
---
United StatesMNKA
Manuka Inc
7.6M
-3.9x
---
United StatesTRVN
Trevena Inc
8.4M
-0.2x
---
United StatesLGVN
Longeveron Inc
7.8M
-0.3x
---
United StatesTHER
Theralink Technologies Inc
6.2M
-0.4x
---
United StatesVCNX
Vaccinex Inc
8.7M
-0.1x
---
As of 2024-03-28

Company Information

Pasithea Therapeutics Corp. is a biotechnology company. The Company is primarily focused on the discovery, research and development of treatments for Central Nervous System (CNS) disorders and RASopathies. The Company operates through two segments: Therapeutics and Clinics. Its Therapeutics segment performs activities related to the discovery, research, and development of treatments for CNS disorders and other diseases. Its Clinics segment provides business support services to anti-depression clinics in the United Kingdom and in the United States. Its therapeutic pipeline consists of four programs. Its lead product candidate, PAS-004, is a macrocyclic mitogen-activated protein kinase (MEK) inhibitor for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and Noonan syndrome, as well as lamin A/C (LMNA) cardiomyopathy and a number of oncology indications. Its other three programs are in the discovery stage.

Contact Information

Headquarters
1111 Lincoln RoadMIAMI BEACH, FL, United States 33139
Phone
786-977-3380
Fax
---

Executives

Executive Chairman, Co-Founder
Lawrence Steinman
Chief Executive Officer, Director
Tiago Marques
Chief Financial Officer
Daniel Schneiderman
Chief Development Officer
Graeme Currie
Independent Director
Simon Dumesnil

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$7.4M
Revenue (TTM)
$240.7K
Shares Outstanding
1.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-12.41
Book Value
$32.64
P/E Ratio
-0.6x
Price/Sales (TTM)
30.9
Price/Cash Flow (TTM)
---
Operating Margin
-7,032.70%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.